- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Immunocompromised host
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antibiotic
- Azithromycin
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Community
- Primary care
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- General population
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Neurostimulation
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Psychotherapy
- Adults (18-64 years)
- Hospital
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Syndromic diagnostic testing
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Human metapneumovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Human metapneumovirus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Steroids
- Dexamethasone
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Vaccination
- VAC∆6
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Oxygen therapy
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Dietary
- Lifestyle intervention
- Curcuma
- Adults (18-64 years)
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Tocilizumab